This whitepaper examines the constraints and challenges inherent in each CAR T study type and how to overcome them with in vivo studies using fully humanized mouse models.
Read Flipbook
JAX NSG-MHC I/II KO mice readily engraft tumors and human PBMCs, have delayed GvHD, and deliver translationally-relevant results for various research applications.
Read Flipbook
Review JAX’s CRS evaluation capabilities and see how a CRS study can help move your CAR T therapeutic into the clinic faster, safer, and more confidently.
Read Flipbook
A glimpse at the wide range of platforms and services JAX offers to help move you from drug discovery to IND filing.
Read Flipbook
Read Flipbook
Although many mammals have immune systems that share important characteristics with humans, certain immune cell types and phenomena are unique to us. As a result, it has been difficult to design...
Learn More
Gabrielle Leclercq, Ph.D. presents findings that Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Watch Video
Brian W. Soper, Ph.D. speaks about the efficacy and safety of therapeutics in immuno-modulatory induced cytokine release syndrome. Dr. Soper discusses human PBMC engraftment profiles; modeling human c
Watch Video
In vivo CRS assays have the potential to simultaneously derisk and accelerate the process of bringing successful therapies to the patients who need them most.
Read Flipbook
Dr. James Keck, Senior Director, Innovation and Product Development, The Jackson Laboratory, presents De-risking Therapeutic Antibody Preclinical Drug Development: Simultaneous Assessment of Efficacy
Watch Video
Dr. Danyig Cai, Associate Director, Innovation & Product Development, The Jackson Laboratory, presents An In Vivo PBMC Humanized Mouse Model for Determining Immunotherapy Related Cytokine Release Synd
Watch Video
May 25, 2021 - In this episode, we discuss how JAX created a unique platform to help predict CRS, addressing this critical challenge earlier in the drug development process.
Watch Video
Immunomodulatory Induced Cytokine Release; What In Vivo Tells You That In Vitro Cannot
Watch Video
The JAX CRS assay has a highly flexible design applicable to a wide variety of human specific immune modulatory therapies. The assay can test both immunostimulatory and immunosuppressive therapies.
Learn More
At The Jackson Laboratory (JAX), we are working with our customers to test CAR T efficacy in solid and disseminated tumors and investigate new models of efficacy and safety testing of this nascent the
Learn More
March 16, 2021 - In this episode, we discuss what CRS is, and which factors can cause CRS.
Watch Video
What is Cytokine Release Syndrome? CRS occurs when the innate and adaptive immune systems are overactivated, releasing too many cytokines, which are substances that can affect other cells.
Watch Video
For the first time ever, drug developers have the option to accurately assess immunotoxicity and drug efficacy in the same study utilizing a novel humanized platform.
Learn More
Read Flipbook
Watch Video
Loading More...
